EVENTS · VRTX
PEERS
EARNINGS
Vertex Pharmaceuticals Incorporated Common Stock represents ownership in Vertex Pharmaceuticals Incorporated, a global biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious diseases. The company’s current portfolio is centered on cystic fibrosis therapies and has expanded into additional specialty disease areas through products such as CASGEVY and JOURNAVX. Vertex serves patients across the United States, Europe, and other international markets, with a business model that combines specialized research, regulatory development, manufacturing, and commercialization capabilities. The company is known for operating in highly scientific and tightly regulated therapeutic markets, where innovation, clinical expertise, and product execution are central to its role. Vertex Pharmaceuticals Incorporated Common Stock is used by investors to track and participate in the performance of a biotechnology business with a strong presence in specialty pharmaceuticals and advanced medicine development.
No company news, with biotechnology stocks higher as a group alongside the market
| Series | 1W | 1M |
|---|---|---|
| VRTX | +3.7% | +9.3% |
| Peers | +1.7% | +5.3% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 43 | 55 |
| QUARTER | EPS EST | EPS ACTUAL | EPS SURPRISE | REACTION |
|---|---|---|---|---|
| Q3 FY2026 | 4.36 | 4.76 | +9.17% | −5.03% |
| Q2 FY2026 | 4.83 | 4.73 | −2.11% | +0.34% |
| Q1 FY2026 | 4.40 | 4.47 | +1.60% | +0.10% |
| Q4 FY2025 | 5.17 | 5.03 | −2.79% | +6.55% |
| Q3 FY2025 | 4.65 | 4.80 | +3.12% | −0.92% |
| Series | 1W | 1M |
|---|---|---|
| VRTX | +3.7% | +9.3% |
| Peers | +1.7% | +5.3% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 43 | 55 |
